Back

CRISPR enriches for cells with mutations in a p53-related interactome, and this can be inhibited.

Jiang, L.; Ingelshed, K.; Shen, Y.; Boddul, S. V.; Iyer, V. S.; Kasza, Z.; Sedimbi, S.; Lane, D. P.; Wermeling, F.

2021-03-10 cancer biology
10.1101/2021.03.10.434760 bioRxiv
Show abstract

CRISPR/Cas9 can be used to inactivate or modify genes by inducing double-stranded DNA breaks1-3. As a protective cellular response, DNA breaks result in p53-mediated cell cycle arrest and activation of cell death programs4,5. Inactivating p53 mutations are the most commonly found genetic alterations in cancer, highlighting the important role of the gene6-8. Here, we show that cells deficient in p53, as well as in genes of a core CRISPR-p53 tumor suppressor interactome, are enriched in a cell population when CRISPR is applied. Such enrichment could pose a challenge for clinical CRISPR use. Importantly, we identify that transient p53 inhibition suppresses the enrichment of cells with these mutations. Furthermore, in a data set of >800 human cancer cell lines, we identify parameters influencing the enrichment of p53 mutated cells, including strong baseline CDKN1A expression as a predictor for an active CRISPR-p53 axis. Taken together, our data identify strategies enabling safe CRISPR use.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.